Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes

The Journal of Clinical Endocrinology and Metabolism
I VardarliJames E Foley

Abstract

Dipeptidyl peptidase-4 (DPP-4) inhibitors block the degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. The aim of the present study was to quantitatively assess the incretin effect after treatment with the DPP-4 inhibitor vildagliptin (V) or placebo (P) in patients with type 2 diabetes. Twenty-one patients (three women, 18 men) with type 2 diabetes previously treated with metformin (mean age, 59 yr; body mass index, 28.6 kg/m(2); glycosylated hemoglobin, 7.3%) were studied in a two-period crossover design. They received 100 mg V once daily or P for 13 d in randomized order. The incretin effect was measured on d 12 (75-g oral glucose) and d 13 ("isoglycemic" iv glucose) based on insulin and C-peptide determinations and insulin secretion rates (ISR). V relative to P treatment significantly increased intact incretin concentrations after oral glucose and insulin secretory responses to both oral glucose and isoglycemic iv glucose (e.g. AUC(ISR oral), by 32.7%, P = 0.0006; AUC(ISR iv), by 33.1%, P = 0.01). The numerical incretin effect was not changed (IE(ISR), V vs. P, 35.7 ± 4.9 and 34.6 ± 4.0%, P = 0.80). DPP-4 inhibition augmented insulin secretory responses both after oral glucose and during...Continue Reading

References

Aug 1, 1992·Endocrine Reviews·H Yki-Järvinen
Jan 1, 1986·Diabetologia·M NauckW Creutzfeldt
Aug 1, 1986·The Journal of Clinical Endocrinology and Metabolism·M A NauckW Creutzfeldt
Sep 1, 1980·The Journal of Clinical Endocrinology and Metabolism·R P EatonJ Standefer
Aug 1, 1996·Computer Methods and Programs in Biomedicine·R HovorkaM A Young
Apr 29, 1998·The Journal of Clinical Investigation·J SchirraM Katschinski
Aug 15, 2001·The Journal of Clinical Endocrinology and Metabolism·M B Toft-NielsenJ J Holst
May 6, 2004·The Journal of Clinical Endocrinology and Metabolism·Bo AhrénAnja Schweizer
Mar 23, 2005·Regulatory Peptides·Michael A Nauck, Juris J Meier
Nov 6, 2007·Frontiers in Bioscience : a Journal and Virtual Library·Carolyn F DeaconJens J Holst
Dec 7, 2007·Best Practice & Research. Clinical Endocrinology & Metabolism·Bo Ahrén
Oct 30, 2008·The Journal of Clinical Endocrinology and Metabolism·David A D'AlessioRichard E Pratley
Jan 28, 2010·American Journal of Physiology. Endocrinology and Metabolism·Kristine J HareFilip K Knop
Mar 11, 2010·Diabetes·Marzieh SalehiDavid A D'Alessio

❮ Previous
Next ❯

Citations

Apr 22, 2011·Diabetes, Obesity & Metabolism·B AhrénJ E Foley
Jan 21, 2012·The Review of Diabetic Studies : RDS·Carolyn F Deacon, Bo Ahrén
Jun 29, 2012·Alimentary Pharmacology & Therapeutics·J E StevensK L Jones
May 2, 2012·Annals of the New York Academy of Sciences·Liza K Phillips, Johannes B Prins
Apr 19, 2015·Biomedical Engineering Online·Yue RuanRoman Hovorka
Dec 14, 2011·Expert Opinion on Pharmacotherapy·André J Scheen
Mar 22, 2016·Endocrinology and Metabolism·Tae Jung Oh
May 15, 2013·American Journal of Therapeutics·Sanjay Chatterjee, Saurav Chatterjee
Jun 12, 2012·The Journal of Clinical Endocrinology and Metabolism·Elza MuscelliEle Ferrannini
Apr 9, 2011·The Journal of Clinical Endocrinology and Metabolism·Yutaka Seino
May 26, 2017·Diabetes, Obesity & Metabolism·Emilie S AndersenJens J Holst
Mar 17, 2019·Diabetes & Metabolism Journal·Soyeon YooGwanpyo Koh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Related Papers

The Journal of Clinical Endocrinology and Metabolism
Jonatan I BaggerTina Vilsbøll
The Journal of Clinical Endocrinology and Metabolism
B Ahrén
American Journal of Physiology. Endocrinology and Metabolism
Elza MuscelliEle Ferrannini
© 2022 Meta ULC. All rights reserved